Synthesis of several new of benzochromenes (4-7), benzochromenopyrimidines (8 and 9), 14-(4-chlorophenyl)-12-(phenyldiazenyl)-14H-benzo [7, 8] [1, 2, 4] triazepine-3-carbonitrile (10a-e, 13) and 9-(benzylideneamino)-7-(4-chlorophenyl)-5-(phenyldiazenyl)-7, 9-dihydro-8H-benzo [7, 8] chromeno [2,3-d] pyrimidin-8-imine (12) , form starting from 2-amino-4-(p-chlorophenyl)-6-phenyldiazenyl-4H-benzochromene-3-carbonitrile (3) . The structure of these new compounds was confirmed using IR, 1 H NMR and 13 C NMR as well as MS spectroscopy. The structure activity relationship studies of the target compounds in agreement with the in vitro essays and confirmed higher potent antimicrobial activity against some of the tested microorganisms. The structure-activity relationship study revealed that the antimicrobial activity of benzochromenopyrimido triazepine nucleus was more beneficial than benzochromenotriazolopyrimidine nucleus for antimicrobial activity.
Introduction
Nowadays, synthetic azo compounds are widely used in different application fields, such as medicines, cosmetics, food, paints, plastics, shipbuilding, automobile industry, cable manufacture [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Moreover azo compounds are known for their antineoplastics [13] , antidiabetics [14] , antiseptics [15] , antibacterial [16] and antitumor [17] . Benzochromene represent a class of heterocyclic compounds endowed with potent antimicrobial agents [18] [19] [20] [21] [22] [23] , antileishmanial [24, 25] , anticancer [26, 27] , antiproliferative [28] , antioxidant [29, 30] , hypertensive [31] , antitumor [32] [33] [34] [35] effects and activities, as well as for the treatment of Alzheimer's disease [36] , schizophrenia disorders [37] , and fused chromene ring systems also displayed blood platelet antiaggregating [38] , antihistaminic [39] , analgesic [40] [41] [42] , hypolipidemic [43] , DNA breaking and mutagenicity activities [44] .
The promising results of previous studies [18, 23, 45 ] prompted us to further extend our research towards the synthesis of annulation of heterocyclic systems of potential biological application. In continuation of our previous work we are reporting here the synthesis of some more analogues of benzochromene moiety as a base unit and antimicrobial activities. The structure activity relationships (SAR) are discussed in this work to correlate between the substituent effects and the activities that aid in drug design.
Experimental

Instrumentation
Melting points were determined with a Stuart Scientific Co., Ltd. apparatus. IR spectra were determined as KBr pellets on a Jasco FT/IR 460 plus spectrophotometer. 1 H NMR and 13 C NMR spectra were recorded using a Bruker AV 400 MHz spectrometer. Mass spectra were measured on a Shimadzu GC/MS-QP5050A spectrometer. All the reagents and solvents were purchased from SigmaAldrich or S.D. fine chemicals limited and used without further purification. Thin-layer chromatography (TLC) was performed using Merck silica gel 60F254 pre-coated plates (0.25 mm) and silica gel (particle size 60-120 mesh) used for column chromatography. Elemental analyses were carried out at the Regional Centre for Mycology and Biotechnology (RCMP, AlAzhar University, Cairo, Egypt) and the results were within ±0.3% of calculated values.
Synthesis
Synthesis of 2-amino-4-(4-chlorophenyl)-6-(phenyl diazenyl)-4H-benzo[h]chromene-3-carbonitrile (3)
A solution of 4-phenyldiazenyl-1-naphthol (1) (2.48 g, 10 mmol) in EtOH (20 mL) was treated with 2-(4-chloro benzylidene)malononitrile (2) (1.88 g, 10 mmol) and piperidine (0.5 mL) under reflux 2 hr. The reaction mixture was heated until complete precipitation. The solid product which formed was collected by filtration and recrystallized from dioxane. This compound was prepared according to the literature [45] 
Synthesis of 4H-benzo[h]chromene derivatives 4 and 5
General procedure: A mixture of compound 3 (4.36 g, 10 mmol), triethyl orthoformate or triethyl orthoacetate (10 mmol) and Ac2O (30 mL) was refluxed for 3 hr. The solvent was removed under reduced pressure and the resulting solid was crystallized from benzene to give compound 4 and 5, respectively (Scheme 1). A stream of NH3 gas was passed through compound 4 (4.92 g, 10 mmol) in methanol (20 mL) at room temperature for 1 h. Then the mixture was left overnight. The solid product was collected and crystalized from benzene (Scheme 2 
Synthesis of N-benzylidene-N'-(4-(4-chlorophenyl)-3-cyano-6-((E)-phenyldiazenyl)-4H-benzo[h]chromen-2-yl) formimidamide (7)
A mixture of compound 6 (4.63 g, 10 mmol), benzaldehyde (0.01 mol), dioxane (20 mL) and piperidine (0. 
Synthesis of 7-(4-chlorophenyl)-5-(phenyldiazenyl)-7,9-dihydro-8H-benzo[7,8]chromeno [2,3-d]pyrimidine-8-thione (8)
Gaseous hydrogen sulfide was bubbled through compound 4 (4.92 g, 10 mmol) in presence of triethylamine (0.5 mL) in methanol for 2 hours. The solid formed was collected to give compound 8 and recrystallized from benzene (Scheme 2). 
Synthesis of 7-(4-chlorophenyl)-8-imino-5-(phenyl diazenyl)-7H-benzo[7,8]chromeno[2,3-d]pyrimidin-9(8H)-amine (9)
A solution of compound 4 (4.92 g, 10 mmol), hydrazine hydrate (5 mL, 99%), in ethanol (50 mL) was stirred at room temperature for h. The yellow solid product formed was washed with cold ethanol, dried and recrystallized from dioxane (Scheme 2 
Synthesis of triazolo derivatives 10a-e
General procedure: A mixture of compound 9 (4.78 g, 10 mmol), triethyl orthoformate or formic acid, (0.01 mol), acetyl chloride or triethyl orthoacetate (0.01 mol), benzoyl chloride (10 mmol) and chloro acettylchloirde (10 mmol) in dry benzene (20 mL) was refluxed for 3 h to give compound 10a-c and 10e, while a mixture of compound 9 (0.01 mol), ethyl cyanoacetate (10 mmol) in absolute ethanol (20 mL) was refluxed for 5 h to give compound 10d, respectively, the solvent was extracted and the resulting product was recrystallized from 1,4-dioxane (Scheme 3). [7, 8] chromeno [3,2-e] [1, 2, 4] triazolo [1,5-c] [7, 8] chromeno [3, 2-e] [1, 2, 4] triazolo [1, 5- [7, 8] chromeno [3, 2-e] [1, 2, 4] triazolo [1, 5- [7, 8] chromeno [3, 2-e] [1, 2, 4] triazolo [1,5- [7, 8] 
14-(4-Chlorophenyl)-12-(phenyldiazenyl)-14H-benzo
2-(14-(4-Chlorophenyl)-12-(phenyldiazenyl)-14H-benzo
2-(Chloromethyl)-14-(4-chlorophenyl)-12-(phenyldiazenyl)-14H-benzo
Synthesis of 14-(4-chlorophenyl)-12-(phenyl diazenyl)-14H-benzo[7,8]chromeno[3,2-e][1,2,4]triazolo [1,5-c]pyrimidine-2(3H)-thione (11)
A mixture of compound 9 (4.78 g, 10 mmol) with carbon disulfide (0.01 mol) and potassium hydroxide (10 mmol) in ethanol (15 mL) was heated under reflux for 5 h. After removal of ethanol, water was added and the resulting alkaline solution was acidified with acetic acid and the precipitate formed collected by filtration, washed with water and dried and crystallized from 1,4-dioxane (Scheme 3 
Synthesis of 9-(benzylideneamino)-7-(4-chloro phenyl)-5-((E)-phenyldiazenyl)-7,9-dihydro-8H-benzo[7,8] chromeno[2,3-d]pyrimidin-8-imine (12)
A mixture of compound 9 (4.78 g, 10 mmol), benzaldehyde (10 mmol), piperidine (0.05 mL) and dioxane (30 mL) was refluxed for 6 h. The solvent was extracted and the resulting product was recrystallized from 1,4-dioxane (Scheme 3 
Antimicrobial Assay
All the newly synthesized compounds 3-13 were screened for their in vitro antimicrobial activity at 25 µg/mL to determine the zone of inhibition against four Gram-positive bacteria: Staphylococcus aureus (RCMB 000106) and Bacillis subtilis (RCMB 000108) and two Gram-negative pathogenic bacteria: Pseudomonas aeruginosa (RCMB 000102) and Escherichia coli (RCMB 000103) using standard antibiotics (Ampicillin) as reference drugs, and two fungi: Aspergillus fumigatus (RCMB 002003) and Candida albicans (RCMB 005002) using standard antibiotics (Mycostatine) as reference drugs. The activities of these compounds were tested by agar diffusion method using Mueller-Hinton agar medium for bacteria and Sabouraud's agar medium for fungi [46, 47] . The tested compounds were dissolved in N,N-dimethylformamide to give a solution of 1 mg/mL. The inhibition zones (diameter of the hole) were measured in millimeters (6 mm) at the end of an incubation period of 48 h at 28 °C; N,N-dimethylformamide showed no inhibition zone. The inhibitory effects of the synthetic compounds against these organisms are given in Figure 1 and Table 1 . Figure 1 . Antimicrobial activity of the tested compounds compared to ampicillin and mycostatine.
Results and discussion
Condensation of 4-phenyldiazenyl-1-naphthol (1) with 2-(p-chlorobenzylidene)malonoitrile (2) (6) , follow by benzaldehyde under reflux afforded Schiff base product 7, while treatment of compound 4 with hydrogen sulfide in ethanol/ triethyl amine at room temperature for 2 h afforded 7-(4-chlorophenyl)-5-(phenyldiazenyl)-7,9-dihydro-8H-benzo [7, 8] chromeno [2,3-d] pyrimidine-8-thione 8. Reaction of compound 4 with hydrazine hydrate in ethanol at room temperature for 2 h afforded 7-(4-chlorophenyl)-8-imino-5-(phenyldiazenyl)-7H-benzo [7, 8] chromeno [2,3-d] pyrimidin-9(8H)-amine (9) (Scheme 2).
The structure of compounds 6-9 were established by spectral data. The IR spectrum of compound 6 showed absorptions at ν 3342, 3328 (NH2), 2203 cm -1 (CN), while compound 7 showed absorption at 3220 (NH), 1310 cm -1 (C=S) and compound 9 showed absorptions at 3320, 3280 (NH2), 3210 cm -1 (NH). Condensation of compound 9 with carboxylic acid derivatives such as formic acid or triethyl orthoformate, acetyl chloride or triethyl orthoacetate, benzoyl chloride, ethyl cyanoacetate, and chloroacetyl chloride, afforded benzochromenotriazolo pyrimidines 10a-e, respectively. Reaction of compound 9 with benzaldehyde in ethanol/piperdine gave the open chain product 9-(benzylideneamino)-7-(4-chlorophenyl) -5-((E)-phenyldiazenyl)-7,9-dihydro-8H-benzo [7, 8] 
Compound 10c was also prepared by cyclization of compounds 12 in dioxane/ piperidine solution under reflux as confirmed by the M.p., mixed M.p., and their identical IR, NMR and MS spectra. Treatment of compound 9 with carbon disulfide in alcoholic potassium hydroxide solution gave the 14-(4-chlorophenyl)-12-(phenyldiazenyl)-14H-benzo [7, 8] The structure of compounds 10-13 were established by spectral data. The IR spectrum of compound 11 showed absorptions at 3300 (NH), 1043 cm −1 (C=S), compound 12 showed absorptions at 3211 cm -1 (NH) and compound 13 showed absorptions at 3340, 3332 (NH2), 2217 cm −1 (CN 13 The structure activity relationship studies of compounds 3-13 revealed that compounds 10d, e, 12 and 13 with inhibitory effects of 28.1±0.3, 29.1±0.6, 28.7±0.1 and 28.5±0.3 µg/mL good activities than the against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and Aspergillus fumigatus, respectively, compared to the standard antibiotics, ampicillin and mycostatine as reference drugs. Other compounds showed almost equipotent activities or were inactive, implying that the benzochromenotriazolopyrimidine and benzochromenepyrimidine nucleus was more active than the benzochromene and 2-methyleneaminobenzochromene.
Compounds 10a-e, 12, and 13 were found to be the with inhibitory effects ranging 27.4±0.1 to 29.4±0.7 µg/mL more activities as compared to the standard antibiotics ampicillin and mycostatine, while compounds 9 and 11 with inhibitory effect of 13.7±0.2 to 19.2±0.4 µg/mL were exhibited moderate activities as compared to the standard antibiotics ampicillin and mycostatine and compounds 3 and 8 showed moderate activity against Pseudomonas aeruginosa with inhibitory effect ranging 16.6±0.1 and 18.2±0.1 µg/mL as compared to the standard antibiotics ampicillin, while compounds 3, 4, 5, 6 , 7 and 8 moderate to weak activity against Staphylococcus aureus, Bacillis subtilis and Pseudomonas aeruginosa with inhibitory effect ranging 13.2±0.3 and 18.1±0.1 µg/mL as compared to the standard antibiotics ampicillin. Compounds 4, 5, 6 and 7 inactive against Pseudomonas aeruginosa, while compounds 3, 4, 5, 6, 7 and 8 inactive against Escherichia coli, and Aspergillus fumigatus, respectively, compared to the standard antibiotics, ampicillin and mycostatine as reference drugs.
Conclusions
In conclusion, a series of novel methyleneaminobenzochemene, benzochromenotriazolopyrimidine were synthesized successfully in good yield, starting from 4H-benzochromene derivative. All the new compounds were fully spectroscopically characterized. The title compounds were synthesized as new compounds with antimicrobial activity in vitro. Compounds 4, 5, 6 and 7 inactive against Pseudomonas aeruginosa, while compounds 3, 4, 5, 6, 7 and 8 inactive against Escherichia coli, and Aspergillus fumigatus, respecttively, compared to the standard antibiotics, ampicillin and mycostatine as reference drugs, while compounds 10a-e, 12, 13 showed high to good activities compared to the standard antibiotics, The structure-activity relationship study revealed that the antimicrobial activity of benzochromenopyrimidotriazepine nucleus was more beneficial than benzochromenotriazolopyrimidine nucleus for antimicrobial activity.
